A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide

Inclusion Criteria: * Men and women between 20 and 55 years of age * BMI of 18-35 inclusive * Able to understand and sign informed consent form * Willing and able to be confined at the clinical research center 8.5 days * Women who are post-menopausal, surgically sterilized, or agree to use effective form of birth control * Women of child bearing potential with a negative pregnancy test at screening and check-in * Medically healthy with normal clinical results and ECG/lab profiles at screening and check-in Exclusion Criteria * Donated 1 pint or more of blood/blood products within 56 days prior to study or received plasma within 7 days prior to study * Pregnancy or become pregnant * Participated in another investigational trial 30 days prior * Physical examination/medical history indicates clinical condition or concurrent illness unsuitable for study * History/presence of clincally significant disease of any body system * History/evidence of congenital hon-hemolytic hyperbilirubinemia * History/evidence of gall stone disease, stomach or intestinal surgery * History/evidence of colorectal cancer * History/evidence of GI disease, e.g., malabsorption, Crohn's Disease, etc. * History/evidence of skin rashes or dermatitis * Taking prescription or over the counter medication (with the exception of oral contraception) during the 7 days preceding confinement to the clinical unit